CAR T-cell Therapy Market Size, Share & Trends Report

CAR T-cell Therapy Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region and Segment Forecasts

Market Segmentation

CAR T-cell Therapy Product Outlook (Revenue in USD Million, 2018 - 2030)
- Abecma (idecabtagene vicleucel)
- Breyanzi (lisocabtagene maraleucel)
- Carvykti (ciltacabtagene autoleucel)
- Kymriah (tisagenlecleucel)
- Tecartus (brexucabtagene autoleucel)
- Yescarta (axicabtagene ciloleucel)
- Others
CAR T-cell Therapy Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Leukemia
- Lymphoma
- Multiple Myeloma
- Others
CAR T-cell Therapy End Use Outlook (Revenue in USD Million, 2018 - 2030)
- Hospitals
- Cancer Treatment Centers
CAR T-cell Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Product Outlook (Revenue in USD Million, 2018 - 2030)
    - Abecma (idecabtagene vicleucel)
    - Breyanzi (lisocabtagene maraleucel)
    - Carvykti (ciltacabtagene autoleucel)
    - Kymriah (tisagenlecleucel)
    - Tecartus (brexucabtagene autoleucel)
    - Yescarta (axicabtagene ciloleucel)
    - Others
  - North America Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Leukemia
    - Lymphoma
    - Multiple Myeloma
    - Others
  - North America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Cancer Treatment Centers
  - U.S.
    - U.S. Product Outlook (Revenue in USD Million, 2018 - 2030)
      - Abecma (idecabtagene vicleucel)
      - Breyanzi (lisocabtagene maraleucel)
      - Carvykti (ciltacabtagene autoleucel)
      - Kymriah (tisagenlecleucel)
      - Tecartus (brexucabtagene autoleucel)
      - Yescarta (axicabtagene ciloleucel)
      - Others
    - U.S. Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Cancer Treatment Centers
  - Canada
    - Canada Product Outlook (Revenue in USD Million, 2018 - 2030)
      - Abecma (idecabtagene vicleucel)
      - Breyanzi (lisocabtagene maraleucel)
      - Carvykti (ciltacabtagene autoleucel)
      - Kymriah (tisagenlecleucel)
      - Tecartus (brexucabtagene autoleucel)
      - Yescarta (axicabtagene ciloleucel)
      - Others
    - Canada Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
- Europe
  - Europe Product Outlook (Revenue in USD Million, 2018 - 2030)
    - Abecma (idecabtagene vicleucel)
    - Breyanzi (lisocabtagene maraleucel)
    - Carvykti (ciltacabtagene autoleucel)
    - Kymriah (tisagenlecleucel)
    - Tecartus (brexucabtagene autoleucel)
    - Yescarta (axicabtagene ciloleucel)
    - Others
  - Europe Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Leukemia
    - Lymphoma
    - Multiple Myeloma
    - Others
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Cancer Treatment Centers
  - UK
    - UK Product Outlook (Revenue in USD Million, 2018 - 2030)
      - Abecma (idecabtagene vicleucel)
      - Breyanzi (lisocabtagene maraleucel)
      - Carvykti (ciltacabtagene autoleucel)
      - Kymriah (tisagenlecleucel)
      - Tecartus (brexucabtagene autoleucel)
      - Yescarta (axicabtagene ciloleucel)
      - Others
    - UK Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Cancer Treatment Centers
  - Germany
    - Germany Product Outlook (Revenue in USD Million, 2018 - 2030)
      - Abecma (idecabtagene vicleucel)
      - Breyanzi (lisocabtagene maraleucel)
      - Carvykti (ciltacabtagene autoleucel)
      - Kymriah (tisagenlecleucel)
      - Tecartus (brexucabtagene autoleucel)
      - Yescarta (axicabtagene ciloleucel)
      - Others
    - Germany Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Cancer Treatment Centers
- Asia Pacific
  - Asia Pacific Product Outlook (Revenue in USD Million, 2018 - 2030)
    - Abecma (idecabtagene vicleucel)
    - Breyanzi (lisocabtagene maraleucel)
    - Carvykti (ciltacabtagene autoleucel)
    - Kymriah (tisagenlecleucel)
    - Tecartus (brexucabtagene autoleucel)
    - Yescarta (axicabtagene ciloleucel)
    - Other
  - Asia Pacific Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Leukemia
    - Lymphoma
    - Multiple Myeloma
    - Others
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Cancer Treatment Centers
  - China
    - China Product Outlook (Revenue in USD Million, 2018 - 2030)
      - Abecma (idecabtagene vicleucel)
      - Breyanzi (lisocabtagene maraleucel)
      - Carvykti (ciltacabtagene autoleucel)
      - Kymriah (tisagenlecleucel)
      - Tecartus (brexucabtagene autoleucel)
      - Yescarta (axicabtagene ciloleucel)
      - Others
    - China Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Cancer Treatment Centers
  - Japan
    - Japan Product Outlook (Revenue in USD Million, 2018 - 2030)
      - Abecma (idecabtagene vicleucel)
      - Breyanzi (lisocabtagene maraleucel)
      - Carvykti (ciltacabtagene autoleucel)
      - Kymriah (tisagenlecleucel)
      - Tecartus (brexucabtagene autoleucel)
      - Yescarta (axicabtagene ciloleucel)
      - Others
    - Japan Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Leukemia
      - Lymphoma
      - Multiple Myeloma
      - Others
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospitals
      - Cancer Treatment Centers
- Rest of World
  - Rest of World Product Outlook (Revenue in USD Million, 2018 - 2030)
    - Abecma (idecabtagene vicleucel)
    - Breyanzi (lisocabtagene maraleucel)
    - Carvykti (ciltacabtagene autoleucel)
    - Kymriah (tisagenlecleucel)
    - Tecartus (brexucabtagene autoleucel)
    - Yescarta (axicabtagene ciloleucel)
    - Others
  - Rest of World Disease Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Leukemia
    - Lymphoma
    - Multiple Myeloma
    - Others
  - Rest of World End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospitals
    - Cancer Treatment Centers

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments